Volume: 2 Issue: 1
Year: 2025, Page: 8-10, Doi: https://doi.org/10.71325/ajjms.v2i1.25.16
Received: Feb. 17, 2025 Accepted: April 1, 2025 Published: April 2, 2025
Coronary heart diseases are significant contributors to mortality worldwide. Early screening and prediction of the disease could be of immense help to control the mortality associated with the disease. However, for such predictions, the utilization of biomarkers that are accurate would be of immense help. Many traditional cardiac biomarkers, including troponins, creatine kinase-MB (CK-MB), and natriuretic peptides, have been extensively used for diagnosing myocardial injury and risk stratification. However, these markers primarily reflect myocardial damage rather than early disease progression. Emerging evidence suggests that monocyte-specific markers, such as soluble CD14 (sCD14), monocyte chemoattractant protein-1 (MCP-1), and CD16+ monocytes, play a critical role in vascular inflammation and atherogenesis, offering additional predictive value in CHD risk assessment. However, many of these are released in a time-bound fashion. Thus, there are early-stage, late-stage, and delayed markers that have been identified. There is no single definitive marker that has been utilized as a bonafide marker for the establishment of the disease. Though newer markers such as heart-specific fatty acid-binding protein (H-FABP) have been proposed to be of immense importance, there has been relatively less utilization of such markers in the detection of coronary heart disease. H-FABP has gained attention for its rapid release following myocardial ischemia, offering potential advantages in early CHD detection. This review critically evaluates the predictive value of traditional cardiac markers, H-FABP, and monocyte-specific markers in CHD. It aims to assess their individual and combined roles in risk assessment, early diagnosis, and prognosis.
Keywords: Cardiac markers, Cardiovascular disease, Troponins, CKMB, HFABP
Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: coronary heart disease. Am J Med. 2014;127(9):807–812. Available from: https://doi.org/10.1016/j.amjmed.2014.04.015
Chilton R. Pathophysiology of coronary heart disease: a brief review. The Journal of the American Osteopathic Association. 2004;104(S7):S5–S8. Available from: https://pubmed.ncbi.nlm.nih.gov/15467017/
Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circulation Research. 2014;114(12):1852–1866. Available from: https://doi.org/10.1161/circresaha.114.302721
Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends in Cardiovascular Medicine. 2017;27(2):123–133. Available from: https://doi.org/10.1016/j.tcm.2016.07.005
Madjid M, Willerson J. Inflammatory markers in coronary heart disease. British Medical Bulletin. 2011;100:23–38. Available from: https://doi.org/10.1093/bmb/ldr043
Parsanathan R, Jain S. Novel Invasive and Non-invasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases. Metabolic Syndrome and Related Disorders. 2019;18(1):10–30. Available from: https://doi.org/10.1089/met.2019.0073
Nair SM, Pareek A, Jamali MC. Assessment of Biochemical Markers for Early Detection and Monitoring of Cardiovascular Diseases: Myocardial Infarction and Heart Failure. IJPQA. 2024;15(1):288–295.
Dalos D, Spinka G, Schneider M, Wernly B, Paar V, Hoppe U. New Cardiovascular Biomarkers in Ischemic Heart Disease-GDF-15, A Probable Predictor for Ejection Fraction. Journal of Clinical Medicine. 2019;8(7):924. Available from: https://doi.org/10.3390/jcm8070924
Ecollan P, Collet JP, Boon G, Tanguy ML, Fievet ML, Haas R. Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay. Int J Cardiol. 2007;119:349–354. Available from: https://doi.org/10.1016/j.ijcard.2006.09.003
Ishii J, Wang JH, Naruse H, Taga S, Kinoshita M, Kurokawa H. Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem. 1997;43(8):1372–1378. Available from: https://doi.org/10.1093/clinchem/43.8.1372
Das UN. Heart-type fatty acid-binding protein (H-FABP) and coronary heart disease. Indian Heart Journal. 2016;68(1):16–18. Available from: https://doi.org/10.1016/j.ihj.2015.07.030
Vupputuri A, Sekhar S, Krishnan S, Venugopal K, Natarajan KU. Heart-type fatty acid- binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain. Indian Heart Journal. 2015;67(6):538–542. Available from: https://doi.org/10.1016/j.ihj.2015.06.035
© 2025 Published by Laxmi Memorial Education Trust. This is an open-access article under CC BY 4.0 license. (https://creativecommons.org/licenses/by/4.0/)
M I Ashad, Maithili Acharya, Vanitha S Shetty, Manjula Shantaram. Implication of Traditional Cardiac Markers and Myocyte-Specific Markers for the Prediction of Coronary Heart Diseases. AJ J Med Sci. 2025;2(1):8–10